Autophagy relieves the function inhibition and apoptosis-promoting effects on osteoblast induced by glucocorticoid

YUDI HAN1, LIHAI ZHANG1, YALING XING2, LICHENG ZHANG1, XIAOJUAN CHEN2, PEIFU TANG1 and ZHONGBIN CHEN2

1Department of Orthopaedics, Chinese People’s Liberation Army General Hospital, Beijing 100853; 2Division of Infection and Immunity, Department of Electromagnetic and Laser Biology, Beijing Institute of Radiation Medicine, Beijing 100850, P.R. China

Received October 26, 2016; Accepted October 20, 2017

DOI: 10.3892/ijmm.2017.3270

Abstract. Autophagy may be a major mechanism by which osteoblasts (OBs) protect against the negative effects of chronic glucocorticoid (GC) usage. OBs are closely associated with the remodeling that occurs in GC-induced osteoporosis (GIO). In osteocytes, in response to stress induced by GCs, several pathways are activated, including cell necrosis, apoptosis and autophagy. However, the role of autophagy in OBs following treatment with excess GCs has not been addressed. In the current study, confocal microscopy observation of green fluorescent protein-microtubule-associated protein 1 light chain 3β (LC3) punctuate, and western blotting for LC3II and Beclin 1 were performed for detection of autophagy in the MC3T3-E1 osteoblastic cell line. Flow cytometry and western blotting were used for the examination of apoptosis and expression of Bax apoptosis regulator (Bax)/apoptosis regulator Bcl-2 (Bcl-2). The expression of genes associated with osteoblastic function, runt-related transcription factor 2, α-1 type 1 collagen and osteocalcin, were measured by reverse transcription-quantitative polymerase chain reaction. The results indicated that autophagy was induced in OBs during dexamethasone (Dex) treatment in a dose-dependent manner. The level of autophagy did not continue to increase over time, but peaked at 48 h and then decreased gradually. Subsequently, flow cytometry was used to demonstrate that inhibition of autophagy induced apoptosis in OBs under Dex treatment, and was associated with the upregulation of Bax and the downregulation of Bcl-2 protein expression. Furthermore, the data suggested that the inhibition of autophagy also suppressed the expression of osteoblastic genes. By contrast, the stimulation of autophagy maintained the gene expression level under Dex treatment. The data revealed that autophagy is an important regulator of osteoblastic apoptosis through its interaction with Bax/Bcl-2, and maintains the osteoblastic function of MC3T3-E1 cells following GC exposure. In addition, these results indicated that the suppression of autophagy in OBs under chronic GC therapy may increase the prevalence of GIO and fragility fractures.

Introduction

Chronic glucocorticoid (GC) therapy is widely used in clinical medicine as an effective way in treating skin disease, inflammatory/autoimmune diseases, including rheumatoid arthritis and chronic obstructive pulmonary disease, and preventing organ transplantation rejection (1). However, long-term use of GCs causes various side-effects, and the most common one being GC-induced osteoporosis (GIO) (2). Approximately half of patients with rheumatoid arthritis receiving chronic GCs therapy experience an osteoporotic fracture; base-line data from randomized clinical trials reported the prevalence of vertebral fractures is ~30% (3). It was also reported that long-term intake of GCs leads to bone infarction and osteonecrosis of the femoral head, causing a significant public health issue (4). Bone loss in GIO is a biphasic process, bone resorption significantly increases within the first 3 months, peaks at 6 months, followed by a slower annual loss of ~3% for the duration of GC administration (5). This is caused by the accelerated lifespan of osteoclasts in the early phase of bone resorption. However, in the long term, osteoclastic activity is usually inhibited by GCs (6). By contrast, osteoblasts (OBs) are directly and consistently modulated by GCs, whereby the production of new OBs precursors is decreased and the mature, matrix-secreting OBs experience premature apoptosis. Therefore, although both bone resorption and formation are suppressed by chronic GCs therapy, bone formation is suppressed more than bone resorption (7-9).
These histological characteristics are quite different from those in other forms of osteoporosis in which osteoclasts have an important role. Thus, more attention should be paid to OBs when investigating GIO.

Autophagy is a lysosomal degradation pathway that is essential for cell growth, survival, differentiation, development and homeostasis. It is a highly regulated process that mainly involves the formation of autophagosomes, which will fuse with the lysosomes and form autolysosomes. Subsequently, degradation occurs and the amino acids or other small molecules are delivered to the cytoplasm for energy production or recycling (10). GC therapy leads to accumulation of damaged proteins, oxygen radicals and degraded nucleic acids (11). Autophagy is the only intracellular degradative mechanism known to remove dysfunctional organelles and/or oxidized proteins, and it is also activated as an attempt to survive under stress (12,13). Despite the ability in which autophagy acts as a survival strategy to preserve cell viability, it may also lead to a programmed cell death process, because of the excessive activation of this self-degrading system (14). Therefore, autophagy has been reported as a ‘double-edged sword’ (15). It was previously reported that autophagy was induced prior to apoptosis during lymphoid cell death caused by dexamethasone (Dex) (16). Another study reported that GC treatment could induce autophagy in mouse osteocytes. Inhibition of autophagy led to augmentation of the effects of Gcs on osteocyte viability (11). The autophagic process is also induced in OBs during mineralization, and autophagy deficiency reduced mineralization capacity, which was proved by knockdown of autophagy-essential genes and OB-specific autophagy-deficient mice (17).

However, whether autophagy is involved in the effect of Gcs on OBs is unknown. We hypothesize that autophagy is one of the mechanisms by which OBs respond to GC treatment. In this study, it was investigated whether GC treatment of OBs induced autophagy. In addition, as the association between autophagy and apoptosis was unclear, as previously described, whether suppression of autophagy altered the negative effects of exogenous Gcs on OBs was also examined. The present observations may offer a novel finding that autophagy is a major mechanism by which OBs protect themselves against the detrimental effect of Gcs.

Materials and methods

Reagents and antibodies. The enhanced green fluorescent protein-microtubule-associated protein 1 light chain 3β (eGFP-LC3B) plasmid was provided by Dr Shaobo Xiao (Huazhong Agricultural University, Wuhan, China) (18). The antibodies used were: anti-microtubule-associated protein 1 light chain 3β (anti-LC3B; cat. no. L7543; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany); anti-Beclin 1 (cat. no. PD017; MBL International Co., Woburn, MA, USA); anti-BAX apoptosis regulator (Bax; cat. no. 50599-2-Ig; Proteintech, Chicago, IL, USA); anti-apoptosis regulator Bcl-2 (Bcl-2; cat. no. PRS3335; Sigma-Aldrich; Merck KGaA); anti-β-actin (cat. no. AA128; Beyotime Institute of Biotechnology, Haimen, China). Dex (cat. no. D4902), 3-methyladenine (3-MA; cat. no. M9281) and rapamycin (cat. no. R8781) were all obtained from Sigma-Aldrich (Merck KGaA). Dex, rapamycin and 3-MA were all dissolved in dimethyl sulfoxide (cat. no. D4540; Sigma-Aldrich; Merck KGaA). The stock solution concentrations were 500 µmol/l for rapamycin, 100 mmol/l for 3-MA. The working solution concentrations were 500 nmol/l for rapamycin and 400 µmol/l for 3-MA.

Cell culture. The MC3T3-E1 cell line was obtained from the Cell Resource Center, Peking Union Medical College (Beijing, China; the headquarters of National Infrastructure of Cell Line Resource). The cell line was confirmed to have no mycoplasma contamination by polymerase chain reaction (PCR). Its species origin was confirmed by PCR. The identity of the cell line was authenticated with Short Tandem Repeat profiling (CODIS; FBI). All the results can be viewed at www.cellresource.cn. Cells were cultured in α-minimum essential medium (cat. no. 12571-063) with 10% (v/v) fetal calf serum (cat. no. 16140-071; both from Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and antibiotics (100 IU/ml penicillin G and 100 Ag/ml streptomycin) in a humidified incubator with 5% CO2 at 37°C. A total of 5x105 cells/well were cultured in 6-well plates and then exposed to Dex of various doses at 10−8, 10−6 and 10−4 mol/l for 24, 48, 72 and 96 h. Autophagy inhibitor 3-MA was added to cells 1.5 h before incubated with Dex as negative control group. Autophagy agonist rapamycin was added 6 h ahead of each time-point as positive control group. Culture medium was replaced with the same concentration GC at interval of 48 h.

Confocal microscopy. MC3T3-E1 cells were cultured on glass coverslips in 35-mm plates. For the detection of autophagosomes, eGFP-LC3B plasmid (2.5 µg/well) was transfected into 1x105 cells/well using Lipofectamine® LTX and Plus reagent (cat. no. 15338-100; Invitrogen; Thermo Fisher Scientific, Inc.) according to manufacturer’s instructions. Cells were then treated with 10−8, 10−6 and 10−4 mol/l Dex in complete culture medium for 24, 48, 72 and 96 h. Rapamycin (500 nmol/l) was added 6 h before each time-point as positive control, and 250 µmol/13-MA was added 1.5h before Dex as negative control. Following fixation with phosphate-buffered saline (PBS) containing 4% (w/v) paraformaldehyde at 37°C for 30 min and staining with 0.1 µg/ml DAPI at 37°C for 1 min, glass coverslips were observed under a Zeiss LSM 510 confocal fluorescence microscope (Carl Zeiss AG, Oberkochen, Germany). Cells containing three or more GFP-LC3 puncta were defined as autophagy-positive. The percentage of cells with characteristic punctate GFP-LC3 staining relative to all GFP-positive cells was calculated as previously described (19). Three random fields were counted, and three independent experiments were performed. Analysis of images was performed using ImageJ (National Institutes of Health, Bethesda, MD, USA).

Western blot analysis. MC3T3-E1 cells were seeded into 6-well plates and incubated at 37°C for 18 h. Cells were subsequently treated with Dex at different concentrations for 24-96 h as previously described. At each time-point, cells were washed with PBS twice and incubated in a cold buffer containing 0.5% Triton X-100, 150 mmol/l NaCl, 12.5 mmol/l β-glycerophosphosphate, 1.5 mmol/l MgCl2, 2 mmol/l EDTA, 10 mmol/l NaF, 1 mmol/l Na3VO4, 2 mmol/l dithiothreitol and protease inhibitor cocktail (cat. no. P8340; Sigma-Aldrich). Centrifugation was performed to obtain cell extracts at
Results

**Dex induces autophagy in a dose-dependent manner in MC3T3-E1 cells.** To determine whether Gcs regulate autophagy, the impact of Dex on formation of autophagosomes in MC3T3-E1 cells was examined. MC3T3-E1 cells were transfected with an eGFP-LC3B-expressing plasmid (22). At 24 h post-transfection, cells were fixed, and examined for evidence of autophagosome formation by confocal fluorescence microscopy. eGFP-LC3 fluorescence microscopy is a well-accepted method for monitoring autophagosome formation (23). As presented in Fig. 1A and B, MC3T3 cells had very low basal autophagic activity, with <2% of cells expressing punctate eGFP-LC3. However, treatment with 10⁻⁸, 10⁻⁶ and 10⁻⁴ mol/l Dex stimulated autophagy, leading to eGFP-LC3 puncta formation in ~50% of cells. A clear redistribution of eGFP-LC3B punctate was observed, indicating the formation of autophagosomes (Fig. 1A). Semi-quantitative analysis as indicated that the increase in puncta-positive cells was dose-dependent, and rapamycin could increase the number of positive cells, while 3-MA effectively reduced it (Fig. 1B).

To validate this finding, western blotting was performed to examine the endogenous expression of LC3, which is a protein involved in the formation of autophagic phagophore membranes. Activation of autophagy is associated with the conversion of LC3 from the cytosolic, soluble form (LC3-I), to the membrane-bound form (LC3-II). This ubiquitin-like modification, termed lipidation, can be illustrated by a change in migration on SDS-PAGE gel and is a sensitive marker for monitoring autophagy (23,24). For further validation, Beclin 1, another marker of autophagy was examined using western blotting. Beclin 1 is involved in the initial step of autophagosome formation (25,26). Collectively, consistent with the eGFP-LC3 fluorescence data, endogenous expression of LC3II and Beclin 1 suggested that Dex increased the autophagic activity in MC3T3-E1 cells in a dose-dependent manner following treatment with Dex for 24 h (Fig. 1C-F).

**Dex-induced autophagic activity peaks at 48 h and decreases over time.** To understand the temporal characteristics of the autophagic activity, cells were transfected with eGFP-LC3B and monitored in the 10⁻⁸ and 10⁻⁴ mol/l Dex-treated groups over time.
eGFP-LC3B puncta formation was observed in cytoplasm as early as 24 h post-transfection (Fig. 2A). In addition, eGFP-LC3B puncta increased at 48 h post-transfection (Fig. 2A and B), in accordance with an increase in LC3II protein expression levels (Fig. 2C). In the 10^{-8} mol/l Dex group, ~15% of cells exhibited cytoplasmic eGFP-LC3B puncta at 24 h post-transfection, and the number increased to 40% at 48 h. The positive rate was 20% at 24 h, and increased to >50% at 48 h in the 10^{-4} mol/l Dex group. However, this trend was not persistent. At 48 h post-transfection, in the 10^{-6} and 10^{-4} mol/l groups, the percentage of cells with eGFP-LC3B puncta decreased and the eGFP-LC3B fluorescence was decreased (Fig. 2B). This was also verified by the LC3II expression levels at 48 h post-transfection. In accordance with these data, the endogenous Beclin 1 protein expression was upregulated in the first 48 h, then reduced substantially afterwards (Fig. 2C and D). Rapamycin was also added to the cells at 96 h. The results showed that the level of Beclin 1 was not significantly elevated, which suggested that autophagy was a transient process in MC3T3-E1 cells (Fig. 2D). This result provided additional support for the feature of Dex-induced autophagic activity in MC3T3-E1 cells.

Dex induced MC3T3-E1 cell apoptosis. Following treatment with various concentrations of Dex, cell apoptosis was
detected by Annexin V/PI double staining. Flow cytometry assays indicated a substantial increase in the FITC-positive population among cells treated with $10^{-6}$ and $10^{-4}$ mol/l Dex, compared to non-treated group (P<0.05). And the difference between $10^{-8}$ mol/l and non-treated group has no statistical significance (P>0.05). But in general, the apoptotic population was increased in a dose-dependent manner (Fig. 3a and B).

Dex-induced autophagy protects MC3T3-E1 cells from undergoing apoptosis. To investigate the effect of autophagy on apoptosis, 3-MA, a potent pharmacological inhibitor of autophagy, was used to suppress Dex-induced autophagy. By contrast, rapamycin was used to increase Dex-induced autophagy. The flow cytometry analysis demonstrated that 3-MA alone did not cause a marked increase in apoptosis and cell death (Fig. 4B), thus that pretreatment with 3-MA was able to block autophagy in MC3T3-E1 cells without significant cytotoxicity. However, 3-MA significantly induced apoptosis at 48 h when combined with Dex exposure (P<0.05; Fig. 4A and B). This result indicated that suppression of autophagy by 3-MA was able to increase Dex-induced damage in MC3T3-E1 cells. To further confirm that apoptosis could be modulated by the regulation of autophagy, western blotting was performed to detect the expression of Bax and Bcl-2. As displayed in Fig. 4C and D, the expression of Bax was not decreased in the $10^{-8}$ mol/l Dex groups compared with the control group (P>0.05). However, when co-treated with 3-MA, Bax expression was significantly upregulated compared with Dex treatment alone. By contrast,
Bax was significantly decreased compared with Dex only treatment when co-treated with rapamycin (P<0.05; Fig. 4C). Unlike Bax, which is a pro-apoptosis protein, Bcl-2 is an anti-apoptosis protein. As shown in Fig. 4D, compared with Dex-only treatment, Bcl-2 expression was increased when cells were co-treated with rapamycin, but was reduced by co-treatment with 3-MA (P<0.05). These results indicated that the blockage of autophagy enhanced the apoptotic effects of Dex in MC3T3-E1 cells. Autophagy induced by Dex served a protective function, and it can be enhanced by promotion of this process.

**Autophagy deficiency interferes with osteoblastic function in MC3T3-E1 cells.** To further investigate whether autophagic deficiency may aggravate the inhibitory action of Dex by reducing the osteoblastic function in MC3T3-E1 cells, the expression of osteoblastic-associated genes was determined. As expected on the basis of previous findings in these osteoblastic cells (27), exposure to GCs was downregulated the expression of Runx2, Colla1 and Ocn (Fig. 5A), which are markers of bone matrix synthesis ability. Treatment of MC3T3-E1 cells with 3-MA alone did not reduce the expression of these genes (P>0.05; Fig. 5B), and treatment with rapamycin alone did not promote their expression, thus making 3-MA and rapamycin practical tools as autophagy-inhibitor and autophagy-inducer in this study (Fig. 5B). The results demonstrated that pretreatment with 3-MA significantly reduced Runx2, Colla1 and Ocn gene expressions in cells exposed to Dex. Additionally, rapamycin promoted the expression of Ocn compared to Dex treatment (Fig. 5C).

**Discussion**

GCs are effective anti-inflammatory and autoimmune modulating agents, but excessive use or chronic GC therapy alters bone metabolism and produces GO, leading to bone fragility.
and bone fractures (28). Unlike senile and postmenopausal osteoporosis, in which osteolysis is activated by the increased population and function of osteoclasts, GIO is predominantly caused by the impaired function of osteogenesis (29). OBs have a central role in bone formation, and GCs directly inhibited cellular proliferation and differentiation of OB lineage cells (30), and reduce OB maturation and activity (31). GCs also induce OB and osteocyte apoptosis in vivo (32). In the current study, flow cytometry was used to demonstrate that apoptosis of MC3T3-E1 cells was induced by Dex in a dose-dependent manner. However, the mechanism of apoptosis was not clear. The expression of Bax is closely associated with mitochondrial apoptosis, which is an important factor in the regulation of cell apoptosis (33). The present study demonstrated that selective gene deletion of Bak and Bax in OBs increased their lifespan and thereby cancellous bone mass in the femur (34). Therefore, we hypothesized that Bax may be involved in the osteoblastic apoptosis caused by Dex. The current study demonstrated that Dex induced apoptosis and also induced autophagy in MC3T3-E1 cells. As shown in Fig. 1, LC3II, Beclin 1 and GFP-lc3 puncta were upregulated by Dex in a dose-dependent manner. The process of apoptosis is often accompanied by the occurrence of autophagy (35), however, the association between apoptosis and autophagy is complex (36).

Several studies have reported that inhibition of autophagy results in dysfunction and death of cells, including hemato-
Han et al: The role of autophagy in osteoblastic stem cells, pancreatic β-cells, kidney epithelium, myocardial cells and neurons (37-40). Previous studies suggested autophagy provided a mechanism for osteocytes to survive the stress after GCs exposure in vitro (12,41), thus we hypothesized that suppression of autophagy in MC3T3-E1 cells may also aggravate the impact of GCs on osteoblastic function. The findings of the current study demonstrated that the suppression of autophagy by 3-MA was able to increase Dex-induced apoptosis in MC3T3-E1 cells. Furthermore, the expression of pro-apoptotic protein Bax was also upregulated following co-treatment with 3-MA and Dex, whereas it was downregulated following co-treatment with the autophagy-inducer rapamycin. To further validate the role of autophagy in mitochondrial apoptosis, the expression of Bcl-2 was examined. Bcl-2 is located in mitochondria and can stop cytochrome c release into the cytoplasm, and the subsequent activation of caspase-3, by reducing mitochondrial membrane permeability (42). The results of the current study indicated that 3-MA significantly reduced the expression of Bcl-2 compared with the group treated with Dex only. By contrast, Bcl-2 expression was increased by co-treatment with rapamycin. These data indicated that autophagy is a pro-survival mechanism in Dex-treated MC3T3-E1 cells to reduce the incidence of apoptosis and facilitate the survival of the cells. The potential mechanism may be via regulation of Bax/Bcl-2 by autophagic process through the mitochondrial pathway. A notable finding produced by the flow cytometry analysis was that there was a marked increase in the apoptotic cell population after 72 h of treatment with Dex (Fig. 3), in comparison to the relative slower increase prior to 72 h. This may be due to the decline of the activity of autophagy following the peak at 48 h, as indicated by the confocal fluorescence microscopy data, resulting in a decreased ability to relieve the negative effect of Dex on MC3T3-E1 cells. This result suggested that autophagy may not be consistently protective if stress lasts for a prolonged time, particularly under chronic GC therapy. Therefore, this indicates that the suppression of autophagy may have an important role in the dysfunction of osteogenesis during long-term intake of GCs.

Furthermore, in accordance with the finding that autophagy facilitated the survival of cells, osteogenic gene expression was also examined by RT-qPCR in order to determine whether autophagy altered the effect of Dex on osteoblastic function. Dex reduced the gene expression of Runx2, Colla1 and Ocn, particularly at relatively higher concentrations. The expression of these genes was also determined in cells following co-treatment with 3-MA and rapamycin, with the results suggesting that osteogenic gene expression was suppressed by 3-MA and induced by rapamycin. These results indicated that autophagy not only altered the process of apoptosis, but also the function of osteoblastic cells.

In conclusion, the findings of the current study demonstrate that excess GC stimulates the process of autophagy in MC3T3-E1 cells, and inhibition of this phenomenon mediates the negative effects of Dex on cell proliferation and osteoblastic function. These results indicate that activated autophagy is a self-protective mechanism used by OBs to oppose the stress induced by excess GC.

Figure 5. Autophagy has a protective effect on osteoblastic gene expressions of MC3T3-E1 cells under Dex treatment. MC3T3-E1 cells were treated with various doses of Dex. (A) Osteogenesis-associated genes Runx2, Colla1 and Ocn were examined by reverse transcription-quantitative polymerase chain reaction. *P<0.05 vs. control; †P<0.05 vs. control. (B) Cells treated with 3-MA (400 µmol/l) or RAPA (500 nmol/l) alone were also examined, no significant difference was detected (P>0.05). (C) Cells were co-treated with Dex and 3-MA or RAPA. *P<0.05 vs. Dex group; †P<0.05 vs. Dex group. Dex, dexamethasone; Runx2, runt-related transcription factor 2; Colla1, α-1 type 1 collagen; Ocn, osteocalcin; 3-MA, 3-methyladenine; RAPA, rapamycin.
Acknowledgements

This study was funded by two grants from China, National High-tech R&D Program (863 Program) (grant no. SS2012A041604) and National Natural Science Foundation of China (grant no. 31271000).

References

1. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton L III, Tenenhouse A, Reeve J, Silman AJ, Pols HA, et al: A meta-analyses of prior corticosteroid use and fracture risk. J Bone Miner Res 19: 893-899, 2004.
2. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM and Cooper C: Bone density threshold and other predictors of vertebra fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48: 3224-3229, 2003.
3. Weinstein RS: Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 365: 62-70, 2011.
4. Mankin HJ: Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 326: 1473-1497, 1992.
5. LoCascio V, Bonacci E, Imbimbo B, Ballanti P, Adami S, Milani S, Demazza D and DellaRocca C: Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8: 39-51, 1990.
6. Jia D, O'Brien CA, Stewart SA, Manolagas SC and Weinstein RS: Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 147: 5592-5599, 2006.
7. Hang JM, Glucocorticoid-induced autophagy in osteoblasts is involved in mineralization and bone microtubule acetylation. J Bone Miner Res 26: 657-665, 2011.
8. Li H, Qian W, Weng X, Wu Z, Li H, Zhuang Q, Feng B and Bian Y: Glucocorticoid receptor and sequential P53 activation by dexamethasone mediates apoptosis and cell cycle arrest of osteoblastic MC3T3-E1 cells. PLoS One 7: e37030, 2012.
9. Naves MA, Pereira RM, Comodo AN, de Alvarenga EL, Caparvo VF and Teixeira VE: Effect of dexamethasone on human osteoblasts in culture: involvement of β1 integrin and integrin-linked kinase. Cell Biol Int 35: 1147-1151, 2011.
10. Mizushima N: Physiological functions of autophagy. Curr Top Microbiol Immunol 335: 71-84, 2009.
11. Xia X, Kar R, Ghufran-Henchiri J, Yao W, Lane NE, Bonewald LF, Biswas SK, Lo WK and Jiang JX: Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res 25: 2479-2488, 2010.
12. He C and Klionsky DJ: Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet 43: 67-93, 2009.
13. Martinet W, Agostinis P, Vanhoecke B, Dewaele M, Mizushima N, Yoshimori T and Levine B: Methods in molecular biology 335: 71-84, 2009.
14. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agustinis P, Aguirre-Ohso JA, et al: Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8: 445-544, 2012.
15. Mizushima N, Yoshimori T and Levine B: Methods in mammalian autophagy research. Cell 140: 313-326, 2010.
16. Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotani N, Maejima I, Shirahama-Noda K, Ichimura T, Isobe T, et al: Two Beclin 1-binding proteins. Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol 11: 385-396, 2009.
17. Itakura E, Kishi C, Inoue K and Mizushima N: Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol Biol Cell 19: 5360-5372, 2008.
18. Alm JJ, Heino TJ, Hentunen TA, Viinäinen HK and Arho HT: Transient 100 nM dexamethasone treatment reduces inter- and intra-individual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells. Tissue Eng Part C Methods 16: 659-666, 2012.
19. Dali Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Porter NR and Meunier PJ: Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16: 97-103, 2001.
20. Mazzotti G, Angelia A, Bilezijkan JP, Canalis E and Giustina A: Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17: 144-149, 2006.
21. Canalis E, Bilezikian JP, Angelia A and Giustina A: Perspectives on glucocorticoid-induced osteoporosis. Bone 34: 593-598, 2004.
22. Weinstein RS: Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2: 65-73, 2001.
23. Weinstein RS, Jilka RL, Parfitt AM and Manolagas SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282, 1998.
24. Chipuk JE, McStay GP, Bharti A, Kuwana T, Clarke CJ, Siskind LJ, Obeid LM and Green DR: Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell 148: 988-1000, 2012.
25. Jilka RL, O’Brien CA, Roberson PK, Bonewald LF, Weinstein RS and Manolagas SC: Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates cortical porosity with age. J Bone Miner Res 29: 103-117, 2014.
26. Zhang T, Li Y, Park KA, Byun HS, Won M, Jeon J, Lee Y, Seok JH, Choi SW, Lee SH, et al: Cucurbitacin induces autophagy through mitochondrial ROS production which counteracts to limit caspase-dependent apoptosis. Autophagy 8: 559-576, 2012.
27. Mauri MC, Zalckvar E, Kimchi A and Kroemer G: Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8: 741-752, 2007.
28. Rangaraju S, Verrier JD, Madorsky I, Nicks J, Dunn WA Jr and Notterpek L: Rapamycin activates autophagy and improves myelination in explant cultures from neuroapatheic mice. J Neurosci 30: 11388-11397, 2010.
29. Jiang M, Wei Q, Dong G, Komatsu M, Su Y and Dong Z: Autophagy in proximal tubules protects against acute kidney injury. Kidney Int 82: 1271-1282, 2012.
30. Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, Debnath J and Passegue E: FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature 494: 323-327, 2013.
31. Jung HS, Chung KW, Won Kim J, Kim J, Komatsu M, Tanaka K, Nguyen YH, Kang TM, Yoon KH, Kim JW, et al: Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab 8: 318-324, 2008.
32. Jia Y, Yao W, Guan M, Dai W, Shahnazari M, Kar R, Bonewald L, Jiang XJ and Lane NE: Glucocorticoid dose determines osteocyte cell fate. FASEB J 25: 3366-3376, 2011.
33. Xia HF, Jin XH, Cao ZF, Shi T and Ma X: miR-98 is involved in rat embryo implantation by targeting Bel-xl. FEBS Lett 588: 574-583, 2014.